SAN FRANCISCO, CA--(Marketwire - June 16, 2010) - AmStem Corporation (OTCBB: AMST), a world leader in stem cell research using stem cells collected from the umbilical cord immediately after birth, has found an innovative use for those cord blood stem cells that are unable to be used for transplant or regenerative medicine purposes.
AmStem's President David Stark said, "We are now using Human Conditioned Stem Cell Media or HCSM, which we have found provides the skin with vital proteins and supplements to make it healthy, balanced and rejuvenated."
HSCM is a main ingredient in AmStem's facial cream, SteMixx™. SteMixx contains IGF-1, 2, which are polypeptides that are part of a complex system that cells use to communicate with their physiological environment. Almost every cell in the body is affected by IGF-1 including cells in the skin, muscle, bone and liver. IGF-1 also stimulates the growth of cells and the composing of collagen. These and other proteins assist with anti-inflammatory and skin regenerative mechanisms creating a smoother, more youthful appearance.
SteMixx™ along with an extensive line of cosmeceutical and hair restoration products was developed by Dr. Han Hoon, Chairman of AmStem Corporation and Histostem, Ltd., in Seoul, Korea. Histostem, a 90% owned subsidiary of AmStem Inc., which operates one of the largest cord blood banks in the world with over 80,000 units stored for personal and unrelated transplant uses.
In preclinical studies conducted by Dr. Han in 2008, HCSM was shown to promote cell division by stimulating fibroblasts and increasing production of collagen and elastine. The studies also showed that the higher the concentration of HCSM, the higher the increase in the proliferation of skin fibroblasts. SteMixx™ contains one of the highest concentrations of HCSM available in any skin care product in the marketplace. The product is targeted for use by skin care professionals and others in the field.
SteMixx™ has been approved by the Korean FDA as a "functional cream" for the treatment of facial skin disfiguration associated with signs of aging such as wrinkles. Dr. Han noted that "sales in Korea have indicated a strong reception for SteMixx™, the first product release in our line of anti-aging stem cell based cosmeceuticals."
AmStem is currently conducting consumer-based studies in the United States while in discussions with distribution networks and major cosmetic distributors. The Company expects to offer SteMixx™ for sale through fine cosmetic stores and on-line distribution channels in time to reach the year-end holiday market in 2010.
About AmStem Corporation
AmStem Inc. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The Company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The Company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the Company for personal storage and use in the family setting for transplant and regenerative medicine as well as for unrelated transplant uses. The Company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The Company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.
An investment profile on AmStem may be found at http://www.hawkassociates.com/profile/amst.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capability or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in the press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.